General Hematology
Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.
7 May, 2021 | 08:33h | UTCEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Commentary on Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest
5 May, 2021 | 08:37h | UTC
Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
4 May, 2021 | 08:38h | UTCCommentary: EHRA Updates Its Popular ‘Practical’ NOAC Guide – TCTMD
Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination
3 May, 2021 | 05:43h | UTCSee also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention
Study on five million Swedes finds links between blood groups and disease risks
3 May, 2021 | 05:09h | UTCNews Release: Study on five million Swedes finds links between blood groups and disease risks – Karolinska Institutet
Original Study: An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk – eLife
RCT: Tranexamic acid for the prevention of blood loss after cesarean delivery – even though TA resulted in a significantly lower incidence of estimated blood loss, the clinical relevance of the findings was small
30 Apr, 2021 | 08:38h | UTC
Commentaries on Twitter
Another typically "positive" trial for TXA.
"the mean between-group difference was approximately 100 ml …. the clinical relevance of this narrow difference is questionable"
– No difference in RBC transfusions.
– 0.4% vs 0.1% VTE at 3 mos.— Ryan Radecki, MD MS (@emlitofnote) April 28, 2021
NEJM-Prevention of Blood Loss after Cesarean Delivery | tranexamic acid ➡️ significantly lower incidence of EBL greater than 1000 ml or RBC transfusion by day 2 than placebo, but did not result in a ⬇️ incidence of hemorrhage-related secondary outcomes https://t.co/ydF5HgHM0N
— Skeptical Scalpel (@Skepticscalpel) April 28, 2021
AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”
30 Apr, 2021 | 08:25h | UTCNews release: Guidance on treatment for rare blood clots and low platelets related to COVID-19 vaccine – American Heart Association
Review: COVID-19-associated coagulopathy and antithrombotic agents – In non-critically ill hospitalized patients, therapeutic dose anticoagulation may improve clinical outcomes. In critically ill patients, this same treatment does not improve outcomes, and prophylactic dose anticoagulation is recommended
29 Apr, 2021 | 08:46h | UTCRelated: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit
Commentary on Twitter
🆕💥💥State of the Art Review Article @TheLancetHaem by @MiddeldorpS
COVID-19-associated coagulopathy
Excellent explanation for the pathophysiology and great summary for the major RCTs and clinical guidelines https://t.co/NxP06KP2Hm pic.twitter.com/qHzyDsUZpt— Antibiotic Steward🆔🦠Bassam Ghanem (@ABsteward) April 28, 2021
M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage
29 Apr, 2021 | 08:28h | UTC
Systematic Review: Disease‐modifying treatments for primary autoimmune hemolytic anemia
28 Apr, 2021 | 08:09h | UTCDisease‐modifying treatments for primary autoimmune haemolytic anaemia – Cochrane Library
Summary: Treatment for primary autoimmune haemolytic anaemia – Cochrane Library
RCT: Reduced dose direct oral anticoagulants may be a safer option to vitamin K antagonists in hemodialysis patients with atrial fibrillation
27 Apr, 2021 | 09:27h | UTCSafety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial – Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
This study finds that patients on hemodialysis with atrial fibrillation experienced decreased cardiovascular events and major bleeding complications with direct oral anticoagulants compared with vitamin K antagonists https://t.co/6FOKkEXtfN pic.twitter.com/PD6qHaeZjT
— JASN_News (@JASN_News) March 22, 2021
ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
21 Apr, 2021 | 07:11h | UTCSee also: Diagnostic Flow Chart
Commentary on Twitter
The ISTH has released interim guidance on vaccine-induced immune thrombotic thrombocytopenia (#VITT) to inform the management of suspected thrombosis in subjects who have recently received the AstraZeneca or Johnson & Johnson vaccine. https://t.co/qqtQtpywaf pic.twitter.com/wNmjNNDs4z
— ISTH (@isth) April 20, 2021
Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions
21 Apr, 2021 | 07:09h | UTC
COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
21 Apr, 2021 | 07:07h | UTCCommentary: Johnson & Johnson vaccine: EU regulator says blood clot very rare side effect – BBC
Commentary on Twitter
EMA has concluded there is a possible link between TTS (thrombosis & thrombocytopenia syndrome) & the J&J vaccine, & they will be adding it as a rare side effect to the product information: the same as for AZ, but so far reported at a much lower rate…1/n https://t.co/aonOEObeHR
— Hilda Bastian, PhD (@hildabast) April 20, 2021
M-A: Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention
20 Apr, 2021 | 05:40h | UTC
Commentary on Twitter
Great paper on guided vs standard DAPT.
Interestingly outcomes were found to vary according to the strategy used:
ESCALATION was associated with⬇️ISCHEMIC EVENTS (without⬆️bleedings)
DE-ESCALATION was associated with⬇️ BLEEDINGS (without ⬆️ischemic events). https://t.co/y4ys6tvktw— Gregory A. Sgueglia (@GregorySgueglia) April 16, 2021
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
18 Apr, 2021 | 21:43h | UTCCommentaries: Researchers Offer Algorithm for Managing Thrombosis and Thrombocytopenia After COVID-19 Vaccination – NEJM Journal Watch AND Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report – TCTMD AND People with rare blood clots after a COVID-19 jab share an uncommon immune response – ScienceNews
Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”
18 Apr, 2021 | 21:42h | UTCSARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – New England Journal of Medicine
COVID vaccines and blood clots: five key questions
18 Apr, 2021 | 21:40h | UTCCOVID vaccines and blood clots: five key questions – Nature
See also (podcast): Coronapod: could COVID vaccines cause blood clots? Here’s what the science says – Nature
Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine
15 Apr, 2021 | 07:02h | UTCThrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine
Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation
U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots
14 Apr, 2021 | 02:16h | UTCJoint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine – U.S. Food & Drug Administration
Commentaries: Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots – BMJ AND CDC and FDA recommend US pause use of Johnson & Johnson’s Covid-19 vaccine over blood clot concerns – CNN AND US halts J&J COVID vaccine after reports of blood clots – CIDRAP AND U.S. urges pause on use of Johnson & Johnson Covid-19 vaccine after rare blood clotting cases – CIDRAP
Why would a Covid vaccine cause rare blood clots? Researchers have found clues
14 Apr, 2021 | 02:14h | UTCWhy would a Covid vaccine cause rare blood clots? Researchers have found clues – STAT
Related: How could a COVID vaccine cause blood clots? Scientists race to investigate – Nature
Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine
12 Apr, 2021 | 01:20h | UTCPapers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine – TCTMD
Study 1: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination – New England Journal of Medicine
Study 2: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine
EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine
12 Apr, 2021 | 01:18h | UTCEMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine – Health Policy Watch
See also: Johnson & Johnson’s COVID-19 vaccine under scrutiny at EMA after 4 ‘serious cases’ of unusual blood clots – Fierce Pharma AND J&J COVID-19 vaccine under EU review over blood clots, AstraZeneca probe grows – Reuters
WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed
8 Apr, 2021 | 09:09h | UTC
Commentary on Twitter (thread – click for more)
🆕 Interim statement of the #COVID19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on the AstraZeneca vaccine https://t.co/p8XMMAiUne pic.twitter.com/7DMRNFxQsX
— World Health Organization (WHO) (@WHO) April 7, 2021
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.
8 Apr, 2021 | 09:07h | UTCCommentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre